1-(3,4-dichlorophenyl)cyclopentane-1-carbonitrile | 213755-91-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(3,4-dichlorophenyl)cyclopentane-1-carbonitrile
• 英文别名: 1-(3,4-dichlorophenyl)cyclopentanecarbonitrile
• CAS: 213755-91-0
• 化学式: C₁₂H₁₁Cl₂N
• 分子量: 240.132
• InChiKey: LIPSDVBHSHEGGB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  23.8
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-(3,4-dichlorophenyl)cyclopentane-1-carbonitrile 在 sodium hydroxide 作用下， 以 1,3-丙二醇 为溶剂， 生成 1-(3,4-二氯苯基)环戊烷甲酸
  参考文献：
  名称：

  Discovery of N-methyl-1-(1-phenylcyclohexyl)methanamine, a novel triple serotonin, norepinephrine, and dopamine reuptake inhibitor

  摘要：

  The current work discloses a novel cyclohexylarylamine chemotype with potent inhibition of the serotonin, norepinephrine, and dopamine transporters and potential for treatment of major depressive disorder. Optimized compounds 1 (SERT, NET, DAT, IC50 = 169, 85, 21 nM) and 42 (SERT, NET, DAT IC50 = 34, 295, 90 nM) were highly brain penetrant, active in vivo in the mouse tail suspension test at 30 mpk po and were not general motor stimulants. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.01.016
• 作为产物：
  描述：

  1,4-二溴丁烷 、 3,4-二氯苯乙腈 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 以86%的产率得到1-(3,4-dichlorophenyl)cyclopentane-1-carbonitrile
  参考文献：
  名称：

  [EN] MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME
  [FR] MODULATEURS DE LA PROTÉINE PHOSPHATASE 2A (PP2A) ET LEURS PROCÉDÉS D'UTILISATION

  摘要：

  本公开涉及部分与蛋白磷酸酶2A（PP2A）的化学调节剂有关，包括式（I）的化合物。本公开的化合物在治疗、预防和/或改善癌症、糖尿病、自身免疫疾病、固体器官移植排斥、移植物抗宿主病、慢性阻塞性肺疾病（COPD）、非酒精性脂肪性肝病、腹主动脉瘤、慢性肝病、心力衰竭、神经退行性疾病和心肌肥厚方面具有用处。

  公开号：

  WO2022167866A1

文献信息

• PYRIMIDONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE
  申请人：Savira pharmaceuticals GmbH

  公开号：US20140194431A1

  公开（公告）日：2014-07-10

  The present invention relates to a compound having the general formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which are useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.

  本发明涉及具有通式（I）的化合物，可选地以药学上可接受的盐、溶剂合物、多型体、共药、共晶、前药、互变异构体、外消旋体、对映体或二对映体或其混合物的形式出现，这些化合物在治疗、缓解或预防病毒性疾病方面是有用的。此外，还披露了特定的联合疗法。
• [EN] PYRROLIDINE TRIPLE REUPTAKE INHIBITORS<br/>[FR] INHIBITEURS DE TRIPLE RÉABSORPTION À BASE DE PYRROLIDINE
  申请人：SEPRACOR INC

  公开号：WO2010091268A1

  公开（公告）日：2010-08-12

  In various embodiments, the present invention provides cycloalkyl pyrrolidine compounds and methods for their use in the treatment and/or prevention of various diseases, conditions and syndromes, including central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter.

  在各种实施方式中，本发明提供环烷基吡咯烷化合物及其在治疗和/或预防各种疾病、症状和综合征中的用途，包括中枢神经系统（CNS）疾病，如抑郁症、焦虑症、精神分裂症和睡眠障碍，以及其合成方法。该发明还涉及含有本发明化合物的药物组合物，以及抑制内源单胺（如多巴胺、5-羟色胺和去甲肾上腺素）从突触间隙中再摄取的方法，以及调节一个或多个单胺转运体的方法。
• Cycloalkyl Amine Compounds
  申请人：Prexa Pharmaceuticals, Inc.

  公开号：US20150057443A1

  公开（公告）日：2015-02-26

  Cycloalkyl amine compounds of Formula (I), wherein ring A is C 3 -C 6 cycloalkyl, optionally substituted with one or more C 1 -C 3 alkyl, and R 5 is OR S2 , in which R S2 is H or C 1 -C 6 alkyl, or R 5 and R 6 , together with the carbon atom to which they are attached, form C═O, for use in treating CNS disorders, including movement disorders, depressive disorders, sleep disorders, cognitive dysfunctions, obesity, sexual dysfunction and substance abuse.

  式（I）中的环状胺化合物，其中环A为C3-C6环烷基，可选择地取代一个或多个C1-C3烷基，R5为ORS2，其中RS2为H或C1-C6烷基，或R5和R6，与它们连接的碳原子一起形成C═O，用于治疗中枢神经系统疾病，包括运动障碍、抑郁症、睡眠障碍、认知功能障碍、肥胖、性功能障碍和物质滥用。
• Substituted 4-arylmethylene-2-imino-2,3-dihydrothiazoles and derivatives and their pharmaceutical use
  申请人：Knoll Aktiengesellschaft

  公开号：US06187802B1

  公开（公告）日：2001-02-13

  Compounds of Formula I including pharmaceutically acceptable salts thereof in the form of individual enantiomers, racemates, or other mixtures of enantiomers, in which Ar is phenyl, naphthyl or benzo[b]thiophenyl, each of which may be optionally substituted; R1 and R2, which may be the same or different, independently are a) H, b) an alkyl group containing 1 to 6 carbon atoms, c) an alkenyl group containing 3 to 6 carbon atoms, d) a cycloalkyl group containing 3 to 7 carbon atoms, e) a cycloalkylmethyl group in which the ring contains 3 to 7 carbon atoms, f) an aryl or heteroaryl group optionally substituted g) an arylalkyl or heteroarylalkyl group each optionally substituted; or R1 and R2 form an alkylene chain optionally substituted by one or more alkyl groups each containing 1 to 3 carbon atoms, such that, together with the atoms to which they are attached, they form a 5 or 6 membered ring; R3 is a) H, b) an aryl or heteroaryl group each optionally substituted c) an optionally substituted arylmethyl group; or d) an alkoxyalkyl group containing 3 to 6 carbon atoms; and R4 and R5, which may be the same or different, independently are an alkyl group containing 1 to 3 carbon atoms, or R4 and R5 together with the atom to which they are attached form a cycloalkyl ring containing 3 to 6 carbon atoms; processes to prepare such compounds; compositions containing such compounds and their use in the treatment of depression, anxiety, Parkinson's disease, obesity, cognitive disorders, seizures, neurological disorders and as neuroprotective agents; are described.

  公式I的化合物包括其药用可接受盐的单体对映体、混合物或其他对映体混合物，其中Ar为苯基、萘基或苯并噻吩基，每种基可选择性地被取代；R1和R2，可能相同也可能不同，分别为a）H、b）含有1至6个碳原子的烷基基团、c）含有3至6个碳原子的烯基基团、d）含有3至7个碳原子的环烷基基团、e）环中含有3至7个碳原子的环烷基基团、f）可选择性取代的芳基或杂环芳基、g）可选择性取代的芳基烷基或杂环芳基烷基；或者R1和R2形成一个由1至3个碳原子的烷基基团选择性取代的烷基链，与它们连接的原子一起形成一个5或6元环；R3为a）H、b）可选择性取代的芳基或杂环芳基、c）可选择性取代的芳基甲基基团；或者d）含有3至6个碳原子的烷氧基烷基基团；而R4和R5，可能相同也可能不同，独立地为含有1至3个碳原子的烷基基团，或者R4和R5与它们连接的原子一起形成一个含有3至6个碳原子的环烷基环；描述了制备这种化合物的过程；含有这种化合物的组合物及其在治疗抑郁症、焦虑症、帕金森病、肥胖症、认知障碍、癫痫、神经系统疾病和作为神经保护剂中的用途。
• Therapeutic agents
  申请人：Knoll Aktiengesellschaft

  公开号：US05652271A1

  公开（公告）日：1997-07-29

  Compounds of formula I ##STR1## and pharmaceutically acceptable salts thereof in which m is 0, 1 or 2; n is 2, 3, 4 or 5; X is carbonyl or a group of formula II ##STR2## in which R.sub.5 is H or alkyl; Y is an alkylene chain optionally substituted by one or more alkyl groups; Z is an alkylene chain containing 2 to 5 carbon atoms optionally substituted by one or more alkyl groups; R is phenyl optionally substituted by one or more halo substituents or R is naphthyl; and R.sub.1 and R.sub.2, which are the same or different, are H, alkyl, or arylalkyl, provided that when R.sub.1 is benzyl, R.sub.2 is H or methyl; have utility in the treatment of depression, anxiety, Parkinson's disease, obesity, cognitive disorders, seizures, neurological disorders such as epilepsy, and as neuroprotective agents to protect against conditions such as stroke.

  化学式为I ##STR1## 的化合物及其药用盐，其中m为0、1或2；n为2、3、4或5；X为羰基或化学式II ##STR2## 中的一种基团，其中R.sub.5为H或烷基；Y为一条可选择地被一个或多个烷基取代的烷基链；Z为含有2至5个碳原子的烷基链，可选择地被一个或多个烷基取代；R为苯基，可选择地被一个或多个卤素取代，或者R为萘基；R.sub.1和R.sub.2，它们相同或不同，为H、烷基或芳基烷基，但当R.sub.1为苄基时，R.sub.2为H或甲基；在抑郁症、焦虑症、帕金森病、肥胖症、认知障碍、癫痫、癫痫等神经系统疾病的治疗中具有用途，并可作为神经保护剂用于预防中风等疾病。